 | Up a level |
Journal Article
Joerger, Markus, Cassier, Philippe, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Gruellich, Carsten, Grande, Enrique, Navarro, Alejandra, Park, Se Hoon, Gillessen, Silke, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter and Schuler, Martin H. (2018). Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. J. Clin. Oncol., 36 (6). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Joerger, Markus, Cassier, Philippe Alexandre, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Grullich, Carsten, Grande, Enrique, Navarro, Alejandro, Park, Se Hoon, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter and Schuler, Martin H. (2018). Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Kempf, Emmanuelle, Penel, Nicolas, Tournigand, Christophe, Gajate, Pablo, Tan, Daniel Shao-Weng, Cassier, Philippe, Nogova, Lucia, Cathomas, Richard, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Sayehli, Cyrus, Navarro, Alejandro, Park, Se Hoon, Piciu, Ana-Maria, Bender, Sebastian, Nogai, Hendrik, Ellinghaus, Peter, Joerger, Markus and Schuler, Martin H. (2020). Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression. J. Clin. Oncol., 38 (6). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel Shao-Weng, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando 
ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Shaw, Alice Tsang
(2014).
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Nogova, Lucia, Gardizi, Masyar, Christiaan, Marc, Bos, Allardt, Scheffler, Matthias, Mattonet, Christian, Heukamp, Lukas Carl, Schildhaus, Hans-Ulrich, Fuhr, Uwe, Eberhardt, Wilfried, Reis, Henning, Wiesweg, Marcel, Schmid, Kurt Werner, Schoch, Gernot, Ko, Yon-Dschun, Serke, Monika Heidi, Schuler, Martin H., Buettner, Reinhard and Wolf, Juergen (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Nogova, Lucia, Sequist, Lecia V., Cassier, Philippe Alexandre, Hidalgo, Manuel, Delord, Jean-Pierre, Schuler, Martin H., Lim, Wan-Teck ORCID: 0000-0002-4655-0206, Camidge, D. Ross, Buettner, Reinhard, Heukamp, Lukas Carl, Gardizi, Masyar, Scheffler, Matthias, Kambartel, Kato, Ringeisen, Francois Philippe, Sen, Suman, Isaacs, Randi, Joannaert, Maud, Lefebvre, Caroline and Wolf, Juergen
(2014).
Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Tan, Daniel Shao-Weng, Shaw, Alice Tsang, Mehra, Ranee, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraides, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Kim, Dong-Wan
(2014).
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial.
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755